Aushon Biosystems said this week that allergy diagnostics firm Phadia will use the Aushon 2470 Arrayer in its Multiplexing Diagnostics division.
Phadia will use the instrument in research efforts to characterize new allergens and to develop molecular tools, including protein biomarkers, that can be used to diagnose allergy and autoimmunity, Aushon said in a statement.
"In many areas, antigens are very different and require specific buffers or additives. That requires a very robust and reliable printing technology, which the 2470 provides," Christian Harwanegg, chief operating officer for Phadia Multiplexing Diagnostics, said in a statement.
Phadia is the latest of several organizations to have adopted the 2470 platform. This May, the Van Andel Research Institute's Laboratory of Cancer Immunodiagnostics purchased a 2470 for work investigating potential protein biomarkers for pancreatic cancer – in particular for running antibody-lectin sandwich arrays to detect and measure glycosylation of secreted proteins (PM 5/12/2010).
In March the Institute for Molecular Medicine Finland announced it was launching a cell microarray screening research program using the 2470 Arrayer, and in June of 2009, the Broad Institute adopted the platform for small-molecule microarray research.